



## Technical Expert Panel Charter

**TEP Title:** Adverse Event Measures Technical Expert Panel (TEP)

**Measure Contractor Convening the TEP:** FMQAI

**Scope and Objective of TEP Activities:** TEP activities will commence upon candidate notification of final selection, on or after February 15, 2013, and conclude by July 31, 2014. The TEP will focus on developing new outcome-based adverse event measures for the hospital settings with potential for automation via electronic health records (EHRs). The TEP will aim to achieve the following key project objectives:

- Maintain previously developed medication measures and develop new medication measures with the potential for National Quality Forum (NQF)-endorsement;
- Adapt/specify existing NQF-endorsed medication measures and develop new measures for implementation in CMS reporting programs such as the Hospital Inpatient and Outpatient Quality Reporting (IQR and OQR) Programs, the Physician Quality Reporting System (PQRS), and others as directed by CMS, such as long-term care settings and ambulatory care settings;
- Continue to develop new medication measures that address the detection and prevention of adverse medication-related patient safety events that can be used in future Quality Improvement Organization (QIO) SOWs and in CMS provider reporting programs; and
- Identify and specify up to 5 new adverse event measures (non medication-related) that could be used in future QIO programs and CMS provider reporting programs in the hospital setting (inpatient and/or emergency department).

**Description of TEP Duties:** The TEP will evaluate proposed adverse event measures drafted by FMQAI in regard to the four primary measure evaluation criteria used in the NQF consensus endorsement process (importance, scientific acceptability, feasibility, and usability). The TEP will discuss the strengths and weaknesses of the proposed measures and make recommendations regarding measure specifications, inclusion and exclusion criteria, and appropriate risk adjustment as applicable. Additional TEP input may be requested in regard to the update and evaluation of already existing medication measures. TEP members will be required to review briefing materials prior to meetings. Additionally, TEP members will be called upon to review information and provide comments between meetings, as well as be available for possible conference calls to discuss NQF recommendations.

**Estimated Number and Frequency of Meetings:** The TEP will meet once face-to-face in Tampa, Florida, on April 29-30, 2013. In addition, the TEP will participate in up to five subsequent teleconferences—exact dates to be determined—as detailed below.

- June 2013: Webinar/teleconference
- September 2013: Webinar/teleconference
- November 2013: Webinar/teleconference
- April 2014: Webinar/teleconference
- June 2014: Webinar/teleconference



**Member Composition:** The TEP Members (voting) and Federal Guests (non-voting) are listed below in Tables 1 and 2, respectively.

**Table 1: TEP Members (Voting)**

<b>Name</b>	<b>Organization</b>	<b>Location</b>
<b>Dale W. Bratzler</b> DO, MPH	Professor and Associate Dean, College of Public Health, University of Oklahoma Health Sciences Center	Oklahoma City, OK
<b>Mary Brennan-Taylor</b>	Adjunct Research Instructor of Family Medicine, School of Medicine and Biomedical Sciences, University of Buffalo Representing: TEP as Patient Representative	Buffalo, NY
<b>Frank E. Briggs III</b> PharmD, MPH	Vice President, Quality and Patient Safety, West Virginia University Healthcare Representing: American Society of Health-System Pharmacists	Morgantown, WV
<b>Joan Ching</b> RN, MN, CPHQ	Administrative Director, Hospital Quality & Safety, Virginia Mason Medical Center	Seattle, WA
<b>Edward S. Eisenberg</b> MD, FACP	Senior Vice President, Performance Measurement and Strategic Alliances, Pharmacy Quality Alliance	West Orange, NJ
<b>Floyd Eisenberg</b> MD, MPH, FACP	President, iParsimony, LLC	Washington, DC
<b>Marybeth Farquhar</b> PhD, MSN, RN	Vice President of Research & Measurement, URAC	Washington, DC
<b>Frank Federico</b> BS, RPh	Executive Director for Strategic Partners, Institute for Healthcare Improvement	Cambridge, MA
<b>Robert Feroli</b> PharmD, FASHP	Medication Safety Officer, Johns Hopkins Hospital	Baltimore, MD
<b>Tejal Gandhi</b> MD, MPH	Chief Quality and Safety Officer, Partners Healthcare; Board-certified Internist and Associate Professor of Medicine, Harvard Medical School Representing: American Hospital Association	Needham, MA
<b>P. Michael Ho</b> MD, PhD, FACC	Staff Cardiologist, VA Eastern Colorado Health Care System; Associate Professor of Medicine, University of Colorado Denver Representing: American College of Cardiology	Denver, CO
<b>Mark L. Holtzman</b> PharmD	Co-Director, Inpatient Pain Service and Pain Management Service Pharmacist, UC Davis Medical Center; Clinical Professor of Anesthesiology and Pain Medicine, UC Davis School of Medicine Representing: American Academy of Pain Medicine	Sacramento, CA
<b>Clifford Ko</b> MD, MS, MSHS, FACS	Director, ACS Division of Research and Optimal Patient Care; Director, ACS NSQIP; Professor of Surgery and Health Services, UCLA Schools of Medicine and Public Health Representing: American College of Surgeons	Los Angeles, CA



<b>Name</b>	<b>Organization</b>	<b>Location</b>
<b>Janet Maurer</b> MD, MBA, FCCP	Operations Medical Director, National Imaging Associates, Health Dialog; Clinical Professor of Medicine, University of Arizona, College of Medicine, Phoenix Campus; Staff Physician, St. Joseph's Medical Center  Representing: American College of Chest Physicians	Phoenix, AZ
<b>Michael N. Neuss</b> MD	Chief Medical Officer, Vanderbilt-Ingram Cancer Center; Professor of Medicine, Vanderbilt School of Medicine  Representing: American Society of Clinical Oncology	Nashville, TN
<b>Crystal Riley</b> PharmD, RPh, MSHCA, CPHQ	Associate Director, Federal Relations, The Joint Commission	Washington, DC
<b>N. Lee Rucker</b> MSPH	Senior Strategic Policy Advisor, AARP Public Policy Institute	Washington, DC
<b>Edward Septimus</b> MD, FACP, FIDSA, FSHEA	Medical Director, Infection Prevention and Epidemiology Clinical Service Group, HCA Healthcare System; Clinical Professor of Internal Medicine, Texas A & M University  Representing: Infectious Diseases Society of America	Houston, TX
<b>Nathan Spell</b> MD, FACP	Chief Quality Officer, Emory University Hospital; Associate Professor of Medicine, Emory University School of Medicine  Representing: American College of Physicians	Atlanta, GA
<b>Stephen J. Traub</b> MD, FACEP	Assistant Professor in Emergency Medicine and Chair, Department of Emergency Medicine, Mayo Clinic  Representing: American College of Emergency Physicians	Phoenix, AZ
<b>Darren M. Triller</b> PharmD	Senior Director, Quality Improvement, IPRO QIO	Albany, NY

**Table 2: Adverse Event Measures Federal Guests (Non-voting)**

<b>Name</b>	<b>Organization</b>	<b>Location</b>
<b>Mary Andrawis</b> PharmD, MPH	Contract Officer Representative & Medication Safety Co-Lead, Centers for Medicare & Medicaid Services, Center for Medicare & Medicaid Innovation	Baltimore, MD
<b>Andrew Geller</b> MD, LCDR USPHS	Epidemic Intelligence Service Officer, Medication Safety Program, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention	Atlanta, GA
<b>Sherriann Moore</b> MS	Deputy Director, U.S. Department of Health and Human Services, Indian Health Service, Office of Urban Indian Health Programs	Rockville, MD



Name	Organization	Location
<b>Nadine Shehab</b> PharmD, MPH	Senior Service Fellow, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention	Atlanta, GA

**Subgroups (if needed):** Work groups include but are not limited to:

- Anticoagulation
- Glycemic Control
- Renal Dosing
- Other Adverse Event Related - TBD

**Date Approved by TEP:** April 29, 2013